DE69329922T2 - Herstellung eines tetanusimpfstoffes - Google Patents

Herstellung eines tetanusimpfstoffes

Info

Publication number
DE69329922T2
DE69329922T2 DE69329922T DE69329922T DE69329922T2 DE 69329922 T2 DE69329922 T2 DE 69329922T2 DE 69329922 T DE69329922 T DE 69329922T DE 69329922 T DE69329922 T DE 69329922T DE 69329922 T2 DE69329922 T2 DE 69329922T2
Authority
DE
Germany
Prior art keywords
pct
production
tetanus vaccine
sec
date
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69329922T
Other languages
English (en)
Other versions
DE69329922T3 (de
DE69329922D1 (de
Inventor
Anthony James Sheppard
Peter Anthony Knight
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seqirus Vaccines Ltd
Original Assignee
Evans Vaccines Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10719649&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69329922(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Evans Vaccines Ltd filed Critical Evans Vaccines Ltd
Application granted granted Critical
Publication of DE69329922D1 publication Critical patent/DE69329922D1/de
Publication of DE69329922T2 publication Critical patent/DE69329922T2/de
Publication of DE69329922T3 publication Critical patent/DE69329922T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DE69329922T 1992-07-31 1993-05-20 Herstellung eines tetanusimpfstoffes Expired - Lifetime DE69329922T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9216351 1992-07-31
GB929216351A GB9216351D0 (en) 1992-07-31 1992-07-31 Vaccine production
PCT/GB1993/001037 WO1994003206A1 (en) 1992-07-31 1993-05-20 Tetanus vaccine production

Publications (3)

Publication Number Publication Date
DE69329922D1 DE69329922D1 (de) 2001-03-15
DE69329922T2 true DE69329922T2 (de) 2001-05-23
DE69329922T3 DE69329922T3 (de) 2010-12-09

Family

ID=10719649

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69329922T Expired - Lifetime DE69329922T3 (de) 1992-07-31 1993-05-20 Herstellung eines tetanusimpfstoffes

Country Status (14)

Country Link
US (1) US6060067A (de)
EP (1) EP0652771B2 (de)
JP (1) JP3901212B2 (de)
AT (1) ATE199059T1 (de)
AU (1) AU690518B2 (de)
CA (1) CA2141410C (de)
DE (1) DE69329922T3 (de)
DK (1) DK0652771T4 (de)
ES (1) ES2157219T5 (de)
GB (1) GB9216351D0 (de)
GR (1) GR3035683T3 (de)
NZ (1) NZ252253A (de)
PT (1) PT652771E (de)
WO (1) WO1994003206A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0408094A (pt) * 2003-03-13 2006-02-14 Glaxosmithkline Biolog Sa processo para purificação de uma citolisina bacteriana, citolisina bacteriana, conjugado de polissacarìdeo capsular-pneumolisina bacteriano, composição imunogênica, vacina, processo de produção da vacina, método de tratamento ou prevenção de infecção por streptococcus pneumoniae, e, uso da pneumolisina ou do conjugado de polissacarìdeo-pneumolisina bacteriano
CN1641034B (zh) * 2004-01-14 2010-04-28 中国药品生物制品检定所 破伤风毒素重组抗原制备方法及其应用
AU2008263591C1 (en) * 2007-06-14 2013-09-26 The Secretary Of State For Health Chemically modified peptides with improved immunogenicity
GB2456549A (en) * 2008-01-18 2009-07-22 Health Prot Agency Modified botulinum neurotoxin serotype E (BoNT/E) peptides
EP2906239A1 (de) 2012-10-12 2015-08-19 GlaxoSmithKline Biologicals SA Unvernetzte azelluläre pertussis-antigene zur verwendung in kombinationsimpfstoffen
KR102388325B1 (ko) * 2016-10-20 2022-04-18 케이엠 바이올로직스 가부시키가이샤 저분자화 PRP를 사용한 Hib 컨쥬게이트 백신의 제조방법
WO2021176409A1 (en) 2020-03-05 2021-09-10 Sanofi Healthcare India Private Limited Preservative combination for vaccine composition
CN115448981A (zh) * 2022-10-20 2022-12-09 北京智飞绿竹生物制药有限公司 一种吸附破伤风疫苗的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB969772A (en) * 1961-01-05 1964-09-16 Wellcome Found Toxoids and their production
JP2706792B2 (ja) * 1988-11-29 1998-01-28 財団法人化学及血清療法研究所 百日咳毒素のトキソイド化法
AU646019B2 (en) * 1990-02-12 1994-02-03 Smithkline Beecham Biologicals (Sa) Novel vaccine and method therefor

Also Published As

Publication number Publication date
ATE199059T1 (de) 2001-02-15
JPH07509481A (ja) 1995-10-19
EP0652771B2 (de) 2010-07-14
GB9216351D0 (en) 1992-09-16
GR3035683T3 (en) 2001-06-29
DE69329922T3 (de) 2010-12-09
DK0652771T4 (da) 2010-10-25
EP0652771A1 (de) 1995-05-17
CA2141410C (en) 2006-10-31
WO1994003206A1 (en) 1994-02-17
AU690518B2 (en) 1998-04-30
AU4082693A (en) 1994-03-03
DE69329922D1 (de) 2001-03-15
CA2141410A1 (en) 1994-02-17
US6060067A (en) 2000-05-09
PT652771E (pt) 2001-05-31
ES2157219T3 (es) 2001-08-16
EP0652771B1 (de) 2001-02-07
NZ252253A (en) 1996-10-28
ES2157219T5 (es) 2010-10-26
DK0652771T3 (da) 2001-02-26
JP3901212B2 (ja) 2007-04-04

Similar Documents

Publication Publication Date Title
LU91610I2 (fr) Protéine D et ses dérivés pharmaceutiquement acceptables (SYNFLORIX - Vaccin pneumococcique polysaccharidique conjugé (adsorbé)
KR930006160A (ko) L-트레오닌의 제조방법
SE9300140D0 (sv) Solid substrate
ATE167229T1 (de) Katalase, ihre herstellung und verwendung
DE69116305T2 (de) Verfahren zur Herstellung von Trehalulose und Isomaltulose
DE69329922D1 (de) Herstellung eines tetanusimpfstoffes
ATE157988T1 (de) Neuartige prolyl-endopeptidase-inhibitoren sna- 115 und sna-115t, ihre herstellung, und hierbei verwendete stämme
FI92334C (fi) Menetelmä syklosporiinien tuottamiseksi ja menetelmässä käytettävä uusi Tolypocladium-kanta
JPS56106593A (en) Alkali protease m3
NO951750D0 (no) Renset "nontypable" Haemophilus influenzae P5 protein som en vaksine for "nontypable" Haemophilus influenzae stamme
EP0090660A3 (de) Neisseria Gonorrhöe Vakzin
ATE110279T1 (de) Verfahren zur herstellung eines pertussis-toxin- toxoides.
IE32044B1 (en) Process for the manufacture of a tetanus-vaccine
CA2109233A1 (en) Process for Producing Vaccine for Bacterial Toxin Belonging to RTX Toxin Family
DE69115556T2 (de) Wärmebeständige Beta-Galactosyltransferase, ihr Herstellungsverfahren und ihre Verwendung
ES2046184T3 (es) Un procedimiento para preparar un compuesto que es antibiotico a 42867 y sus sales por adicion.
ATE223437T1 (de) Verwendung eines immunglobulinpräparates zur herstellung eines oral anzuwendenden medikaments zur prävention des hämolytischen urämischen syndroms sowie präparat hierfür
RU94003337A (ru) Штамм бактерий morganella morganii - продуцент термолабильного энтеротоксина
ES2141258T3 (es) Enzima y su uso en la preparacion de acido (s)-pipecolico.
DK612188D0 (da) Antibiotikum a/16686 faktorer a'1, a'2 og a'3, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende saadanne forbindelser
SE9403636D0 (sv) Vaccine preparation
JPS572684A (en) Preparation of amylase inhibitor ai-b
ITMI913375A1 (it) Procedimento per la produzione di neuraminidasi
Prado et al. Diphtheria anatoxin industrial purification by gel filtration
Schmauder et al. Coronatine: a phytotoxin produced by Pseudomonas syringae pathovars and its effect on plant cell cultures

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: EVANS VACCINES LTD., OXFORD, OXFORDSHIRE, GB

8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings
8327 Change in the person/name/address of the patent owner

Owner name: NOVARTIS VACCINES AND DIAGNOSTICES LTD., CAMBE, GB